| Financial and Operational Strength
As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn.
The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes.
The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets.
Grab Sources And More Here: VNRX Website. VNRX Presentation. -----
And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look:
#1. VNRX Potential Catalyst - A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside.
Recently, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price target of $2.50.
From Monday's closing valuation, this target suggests a potential upside of 875+%.
Here's some report highlights:
Outlook:
Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements.
The company’s 1st commercial order for Nu.Q Cancer assays was received in November.
The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month.
Papers, posters, conference presentations, webinars etc. continue on a brisk pace. -----
#2. VNRX Potential Catalyst - Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®.
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.
Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented: "We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year."
...
Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:
"We are honored to have the support of our long term collaborator, Hospices Civils de Lyon. Reimbursement is the next step on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives."
"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026."
Read the full article here. -----
#3. VNRX Potential Catalyst - Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment.
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Nu.Q® Biomarker Paper Available on MedRXIV
HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population.
The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) and the U.K.
Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added:
"We are excited to report the findings of this clinical study, which focused on a chronic disease, HS. It paves the way to improve a patient's management through a personalized medicine approach.
This study, together with previously published evidence, demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions.
Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opp. for such indications is significant, with a Total Addressable Market of $3.8Bn..."
...
Read the full article here. -----
#4. VNRX Potential Catalyst - Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test.
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool.
Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.
Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China.
Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented:
"We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well established reference labs.
By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier and help pet owners make timely, informed decisions about cancer care.
The market opp. for Nu.Q® Vet is considerable, with the Total Addressable Market for Canine Screening approximately $100Mn for the U.S., Europe and Japan and would increase to a little under $150Mn with the addition of China."
Read the full article here. -----
#5. VNRX Potential Catalyst - A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data.
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
Frédéric Wuilque, VP-Global Products, Volition commented:
"Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.
Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms."
...
Read the full article here. -----
(NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch
#1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside.
#2. Reimbursement Will Be A Major Milestone Towards Commercialization And Licensing Of Nu.Q®.
#3. Exciting Findings From A Key Clinical Study Could Create A Buzz-Filled Environment.
#4. Two New Centralized Lab Providers Create Availability For Company's Vet Cancer Test.
#5. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. -----
We're officially kicking-off coverage on VolitionRx Limited (NYSE American: VNRX).
Updates will head your way soon. Keep your eyes peeled.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/10/2026 and ending on 02/10/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/vnrx-qzefx/#details | 
0 التعليقات:
إرسال تعليق